FACE-OFF: Team Phantoms vs Team Accelerators: Treatment Strategies for the Management of LS-SCLC and NSCLC

Panelists discuss how adjuvant durvalumab after chemoradiotherapy (PACIFIC trial) established the standard of care for locally advanced non–small cell lung cancer, while the DUART trial showed potential benefits even in frail patients treated with radiation alone, the COAST trial demonstrated improved outcomes by adding trebananib to durvalumab, and the ADRIATIC trial revealed significant survival benefits from adjuvant durvalumab in limited-stage small cell lung cancer.

Panelists discuss how the LAURA trial demonstrated dramatic progression-free survival improvements with adjuvant osimertinib for EGFR-mutated stage III lung cancer, while the SINDAS, NORTHSTAR, and LONESTAR trials explore whether upfront local consolidative radiation therapy to oligometastatic sites can improve outcomes in both EGFR-mutated and nonmutated metastatic disease.

Panelists discuss how radiation oncologists can increase pulmonologist awareness about radiation therapy through multidisciplinary collaboration, educating colleagues about modern treatment capabilities, engaging them in fiducial placement and toxicity management, and positioning radiation oncology as both an upstream and downstream service that can help solve pulmonologists’ clinical challenges.